Management of multiple sclerosis
Multiple sclerosis is a chronic inflammatory demyelinating disease. Several therapies for it exist, although there is no known cure. Administration of high doses of intravenous corticosteroids, such as methylprednisolone, is the routine therapy for acute relapses. Stem cell therapy is being studied.
About Management of multiple sclerosis in brief
Multiple sclerosis is a chronic inflammatory demyelinating disease. Several therapies for it exist, although there is no known cure. The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. Administration of high doses of intravenous corticosteroids, such as methylprednisolone, is the routine therapy for acute relapses. In 1993, interferon beta-1b was the first drug to ever be approved for MS. Glatiramer acetate, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, Siponimod and Cladribine were approved in 2019. Ozanimod was approved in March 2020. Daclizumab, that was once approved, was later withdrawn. Stem cell therapy is being studied. This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded. For confidential support call the Samaritans on 08457 90 90 90, visit a local Samaritans branch or see www.samaritans.org for details. In the U.S. call the National Suicide Prevention Line on 1-800-273-8255 or visit www.suicidepreventionlifeline.org. In Europe, contact the National Institute for Health and Welfare on 0800-9090 or visit the National Institutes of Health on 080-909090 or the European Medicines Agency on 020-908090. In Japan, the Japanese Ministry of Health, Labour and Welfare has no information on the treatment of MS.
It is not known if there is a treatment for MS in Japan, but it is possible to have an MS-like condition in Japan that is more severe than in the United States. For more information on MS in the UK, see the National MS Society’s MS UK website. For information on how to get involved in the MS UK Clinical Trials Network (MSUK), visit the MSUK website or call the UK MS Society on 0808 909090. For details on MS-related conditions in the US, go to the MSuk website or the British MS Society. For additional information, visit the NHS England website and the MS Society of the UK. For the UK and Ireland, the MS Association has a number of support groups for people suffering from MS, including the British Association of Neurologists and the Royal College of Paediatrics and Child Health, which is based at the University of London. For further information, or to get in touch with your local MS charity, call the NICE on 0300 123 9090 or go to http://www.nhs.uk/MS/MS-related-compensation/. For more on the benefits of stem cell therapy for MS, see http:// www.ms-uk.org/stem-cell-therapy-for-MS/. For information about stem cell therapy for MS, visit www.marsuk.uk.
You want to know more about Management of multiple sclerosis?
This page is based on the article Management of multiple sclerosis published in Wikipedia (as of Nov. 16, 2020) and was automatically summarized using artificial intelligence.
